CDMO News news

• 

  7 October 2025

  BBG Advanced Therapies and CELLforCURE Partner for Transatlantic ATMP Manufacturing Solutions

  The partnership enhances global CDMO capacity, offering integrated services for ATMP development and manufacturing, leveraging expertise and infrastructure across the U.S. and Europe.
• 

  1 October 2025

  Terumo Completes Acquisition of WuXi Biologics Plant in Germany

  The acquisition enhances Terumo's CDMO capabilities, expanding services in Europe and the US, focusing on injectable treatments and leveraging advanced manufacturing technologies.
• 

  1 October 2025

  Evonik Awards Nobel Laureate Ben Feringa

  Ben Feringa, Nobel laureate, honored for his work in molecular machines and catalysis, highlighting the importance of academia-industry collaboration for sustainable solutions.
• 

  22 September 2025

  Evonik Introduces MaxiPure® Polysorbate 80 for Injectable Drugs

  MaxiPure® Polysorbate 80 offers ultra-high purity for injectable drugs, enhancing protein stability and solubilization, while ensuring regulatory compliance and formulation reliability.
• 

  17 September 2025

  WuXi Biologics Gains GMP Certification for Three Facilities from Turkey's TITCK

  Three WuXi facilities passed TITCK's inspection, reinforcing their global quality standards and expanding into the Turkish market.
• 

  9 September 2025

  Evonik and Ethris Partner on Nucleic Acid Delivery Platform

  The partnership aims to enhance nucleic acid delivery with a novel lipid nanoparticle platform, improving stability and targeting for therapies and vaccines.

• 

  31 July 2025

  WACKER Q2 Earnings Meet Expectations

  Sales and EBITDA fell due to weak demand and trade uncertainties. Net income was negative. Full-year outlook revised down. Focus on growth, cash, and cost management.
• 

  14 May 2025

  WuXi Biologics Sells Leverkusen Plant to Terumo

  The Leverkusen plant sale aligns with WuXi's strategy to focus on large-scale DP manufacturing in Singapore, enhancing global client solutions and optimizing asset returns. Completion expected in 2025.
• 

  6 December 2024

  WuXi Biologics Hits Key Milestones at Ireland Site with 16,000L PPQ Success and HPRA GMP Approvals

  The Dundalk site completed two successful PPQ runs and received GMP approval, enhancing its role in global biomanufacturing with innovative, sustainable processes and strong regulatory compliance.
• 

  24 September 2024

  PCI Pharma invests $365M in EU and US facilities for advanced drug delivery and device products

  Investments enhance drug-device assembly, packaging, and storage in the US and EU, focusing on injectables and biologics, with new facilities in Illinois and Ireland.
• 

  12 September 2024

  Lilly Invests $1.8 Billion in Irish Manufacturing Expansion

  The $1.8B investment will boost production of Alzheimer's, diabetes, and obesity treatments, create 150 jobs, and enhance sustainability with advanced technologies and a solar farm.
• 

  30 July 2024

  ICIG Acquires Clariant's Bioethanol Plant in Romania

  The site will be run by Corden BioChem, expanding its fermentation capacity. ICIG plans significant investments and will rehire many former employees.
• 

  26 June 2024

  EuroAPI FOCUS-27 Plan: Job Cuts and Facility Divestments

  The FOCUS-27 plan aims to boost competitiveness with €110-120M restructuring costs, €350-400M CAPEX, and €75-80M annual EBITDA by 2027, focusing on high-value APIs and strategic sites.
• 

  19 June 2024

  WACKER and CordenPharma Achieve Pandemic Readiness in June 2024

  The consortium will produce 80 million mRNA vaccine doses annually if needed, following a successful expansion and qualification phase, ensuring pandemic readiness for at least five years.
• 

  11 June 2024

  Merck Invests €62M in New Quality Control Facility

  The new 10,000 sqm facility in Darmstadt will house 135 employees, meet sustainability standards, and enhance quality control for life science products, supporting Merck's €1.5B investment program.
• 

  3 June 2024

  WACKER Launches mRNA Center in Halle, Germany

  The new facility in Halle enables large-scale mRNA production, creating over 100 jobs and supporting Germany's pandemic preparedness with a capacity for 200 million vaccine doses annually.
• 

  5 April 2024

  Pantherna and WACKER Expand mRNA Biopharmaceutical Collaboration

  WACKER's Halle site will produce mRNA-based ARDS treatment using a scalable process. The facility, operational by mid-2024, marks a milestone in their collaboration with Pantherna.
• 

  18 January 2024

  Seqens and Pleryon Collaborate on GMP Polymer for Osteoarthritis Treatment

  Seqens will develop and produce Pleryon's osteoarthritis polymer at its upgraded French facility, enhancing GMP capabilities for medical and pharmaceutical applications.
• 

  14 December 2023

  Alkermes to Sell Athlone Facility to Novo Nordisk

  The $92.5M sale includes a subcontracting period until 2025. Alkermes aims for operational efficiency, while Novo Nordisk gains manufacturing capacity and 400 skilled employees.
• 

  10 November 2023

  Novo Nordisk to Invest €5.6 Billion in Expanding Danish Manufacturing Facilities

  The €5.6 billion investment will expand API and packaging capacity, create 800 jobs, and enhance sustainability. Completion is expected between 2025-2029, with 3,000 external workers during construction.
• 

  13 October 2023

  Lonza to Add New ADC Filling Line at Stein Facility

  The new cGMP filling line will enhance bioconjugate handling and create 115 jobs by 2027, expanding end-to-end ADC manufacturing capabilities and supporting clinical and commercial supply.
• 

  12 June 2023

  Novo Nordisk to Invest €2.1bn in Danish Manufacturing Expansion

  The €2.1bn investment will expand API production in Hillerød, creating 340 jobs by 2029. The facility will enhance production capacity, flexibility, and sustainability for future chronic disease treatments.
• 

  8 May 2023

  WACKER Acquires ADL Biopharma to Boost Biotechnology Business

  The acquisition expands fermentation capacity by 2,000 cubic meters, enhances recovery and purification processes, and aims to grow customer relationships in food, pharmaceutical, and consumer goods sectors.
• 

  5 May 2023

  ORGANICA Feinchemie Joins WeylChem Group After ICIG Acquisition

  The acquisition boosts WeylChem's workforce to 1,500 and sales to €730M. ORGANICA will operate as WeylChem ORGANICA, focusing on custom synthesis and contract manufacturing.
• 

  29 March 2023

  Lonza Expands Drug Product Manufacturing in Visp

  The new cGMP line in Visp is operational, with first batches in April 2023. It supports clinical and commercial needs, enhancing end-to-end solutions and complementing recent site expansions.
• 

  16 February 2023

  Lonza Expands Bioconjugation Facility in Visp

  The expansion includes two new manufacturing suites, enhancing capabilities for clinical and commercial supply, and increasing process, analytical development, and quality control capacity.
• 

  1 July 2022

  Lonza to Build Large-Scale Drug Product Facility in Stein

  The CHF 500M facility, set for 2026 completion, will enhance end-to-end drug product manufacturing, leveraging existing infrastructure and focusing on sustainability with a photovoltaic roof.
• 

  6 April 2022

  WeylChem Opens New Multi-Purpose Plant in France

  The new plant in Lamotte enhances flexibility and capacity for complex molecule synthesis with advanced automation. It includes upgraded equipment for high-temperature and high-pressure operations.
• 

  18 November 2021

  Arxada Invests CHF 20m in Czech Biotech Plant

  The investment will enhance infrastructure, expand technological options, and increase formulation capacity to support a growing customer base and accelerate project development.
• 

  22 September 2021

  Lonza Expands Drug Product Services in Switzerland

  Investment in new filling line and expanded Drug Product Services in Stein and Basel will enhance capabilities for various drug modalities, creating over 70 jobs and supporting clinical and commercial stages.